Advanced glycation end products (AGEs) are the product of non-enzymatic glycation of serum proteins. AGEs increase reactive oxygen species (ROS) formation, which leads to diabetic complications. Phytochemicals exhibit lesser side effects as compared to conventional therapy. In this study, three isomers of coumaric acid (ortho, meta, para) were used to deduce the better one in terms of reducing diabetic complications. For this purpose, human serum albumin (HSA) was incubated with glucose in the absence and presence of isomers for 28 days. To avoid any growth, NaN₃ was added and temperature was kept constant throughout the incubation period. Studies like fluorescence, circular dichroism spectroscopy, fructosamine analysis, free lysine estimation, free thiol group estimation were done. To investigate the ROS production, fluorescence microscopy of isolated lymphocytes using DAPI and dichloro-dihydro-fluorescein diacetate were performed. Molecular docking and molecular dynamic simulations (root-mean-square deviation, root-mean-square fluctuations, radius of gyration and solvent-accessible surface area) of HSA and peroxisome proliferator activated receptor (PPAR) alpha and gamma were also done. It was observed that in glycated protein samples, the level of absorbance, fluorescence, fructosamine and carbonyl group increased along with the loss of secondary structure, free lysine and thiol group. These parameters were found gradually recovered in treated samples. ROS production and apoptosis were found to be reduced in lymphocytes treated with p-Coumaric acid (pCA)-treated protein samples as compared to lymphocyte treated with glycated protein. Computational modelling suggested a stable complex formation of HSA and PPARs with pCA. Results with pCA at 200 µM were consistently better than other two isomers. Our next step is to evaluate this study in rats.Communicated by Ramaswamy H. Sarma.

02 Jul 2024·International Journal of Neuroscience

Effects of protocatechuic acid against cisplatin-induced neurotoxicity in rat brains: an experimental study

Article

Author: Mıs, Leyla ; Mert, Handan ; Yıldırım, Serkan ; Mert, Nihat ; Kerem, Özge

Aims/Objectives: Cisplatin (CIS) is widely used in the treatment of various malignant tumors. The aim of study is to determine the potential protective effects of protocatechuic acid (PCA) on the brain in neurotoxicity induced by CIS in rats.Materials and methods: Forty rats were divided into four groups: 1-Control group: 2- PCA group: PCA was administered orally at a dose of 100 mg/kg/day for 5 weeks. 3-CIS group: 5 mg/kg/week of CIS was administered intraperiteonally 4-PCA + CIS group: The rats were given PCA orally daily for 5 weeks and CIS of 5 mg/kg/week. The brain tissues were used for histopathological examinations and for total antioxidant capacity (TAC), total oxidative state (TOS), oxidative stress index (OSI), tumornecrosis factor-alpha (T NF-α), interleukin 6 (IL-6) Interleukin 1 beta (IL-1β), acetylcholinesterase (AChE), glutamate, gamma aminobutyric acid (GABA), dopamine analyzes in ELISA. WBC, RBC, hemoglobin and hematocrit levels were measured.Results: PCA + CIS group compared to CIS group TOS, OSI, T NF-α, IL-6, IL-1β, AChE, glutamate, WBC levels decreased significantly, while TAC and GABA levels increased statistically significant. With this study, P CA corrected the deterioration in the oxidant / antioxidant status, suppressed neuro-inflammation, decreased AChE activity, partially normalized neurotransmitters, and decreased the increased WBC count. Necrosis seen in the CIS group in histopathological examinations was never seen in the PCA + CIS group.Conclusions: PCA may provide therapeutic benefit when used in conjunction with CIS.

01 Apr 2024·Journal of the Formosan Medical Association

Effectiveness of two same-manufacturer intravenous immunoglobulin for Kawasaki disease

Article

Author: Wu, Kun-Lang ; Lin, Ming-Tai ; Chang, Yu-Jun

BACKGROUNDTo investigate whether two brands of intravenous immunoglobulin (IVIG) from the same manufacturer lead to varied effects when administered to patients with Kawasaki disease.(KD) METHODSClinical characteristics, laboratory data, IVIG response, and coronary arteries change were analyzed between two groups.RESULTSWe included 158 KD cases. The mean age at KD diagnosis was 23 ± 1.39 (range, 2-95) months. In the first IVIG course, 18 (11.4 %) patients were unresponsive. TBSF (brand T) and Privigen (brand P) were administered to 94 and 64 patients, respectively. The brand P group had a significantly longer fever (P < 0.001) and hospitalization (P = 0.007) durations after the therapy and a higher number of IVIG unresponsiveness (P = 0.016) than the brand T group. In the multivariate logistic regression analysis, a high Formosa score (≥3, Odds ratio [OR], 4.939; 95 % confidence interval [CI], 1.199-20.337; P = 0.027), high levels of CRP (≥12 mg/L, OR: 4.257,95 % CI,1.265-14.322; P = 0.019), and treatment with brand P (OR, 3.621; 95 % CI, 1.029-12.677; P = 0.045) were independent risk factors for IVIG unresponsiveness.CONCLUSIONSCompared with brand T, brand P prolonged the fever and hospitalization durations after IVIG treatment and increased the proportion of IVIG treatment unresponsiveness, but it did not infer the coronary arteries sequelae.

100 Deals associated with Chloramphenicol/Fradiomycin Sulfate/Prednisolone

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Skin and skin structure infections	JP	Fuji Chemical Industries Co., Ltd.	15 Mar 1994
Dermatitis	JP	Alfresa Pharma Corp.	09 Nov 1959
Eczema	JP	Alfresa Pharma Corp.	09 Nov 1959
Pyoderma	JP	Alfresa Pharma Corp.	09 Nov 1959
Secondary infection	JP	Alfresa Pharma Corp.	09 Nov 1959

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2020	Not Applicable	HER2 Positive Breast Cancer Neoadjuvant	215	NACT+p+O	xlorfrwymn(eeqephsjeq) = gkubxzosla xwbfsrkrzz (zulytcvqnf ) View more	Positive	25 May 2020
ASCO2018	Not Applicable	HER2 Positive Breast Cancer Neoadjuvant	219	NAC+T	(wklgekvcvf) = gqgyllcpie mvswavgkzu (tntzodhptj ) View more	Positive	01 Jun 2018
				NAC+T+P	(wklgekvcvf) = boleledgfo mvswavgkzu (tntzodhptj ) View more
AACR2017	Phase 2	Metastatic breast cancer	81	Pelareorep + P	(olkwlpqyxx) = pbfqyuipiq suvqvnqgkl (rvulpcfbkz ) View more	Negative	01 Jul 2017
				P	(olkwlpqyxx) = auxenwboko suvqvnqgkl (rvulpcfbkz ) View more
MOSG (ASCO2006)	Phase 3	Metastatic breast cancer	368	X+P	(mejbxlbsdl) = PFS and OS are similar at a median follow-up of 15.5 months zkfwmynobv (fakhluwlvf ) View more	-	20 Jun 2006
				X+T
ASCO2004	Phase 2	Non-Small Cell Lung Cancer Consolidation	-	NVB oral + P	nvzwgefcau(pwiuwbpmpf) = nonbftbajc ixzceylisn (obfbxzjhmv ) View more	Positive	15 Jul 2004
ASCO2004	Not Applicable	Locally Advanced Head and Neck Squamous Cell Carcinoma Neoadjuvant	718	Regimen A: Ifosfamide	(wyhwcwxwjp) = 48.3% patients on D & 49.1% patients on E had grade III & IV neutropenia fjuqzzadho (pppttuuris ) View more	-	15 Jul 2004
				Regimen B: Ifosfamide with cisplatin (I+P)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Chloramphenicol/Fradiomycin Sulfate/Prednisolone

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation